UK Ophthalmology M&A: Private Pay Growth and Investment Trends in 2026

UK Ophthalmology M&A Trends: Private Pay Platforms, NHS Tariff Changes and Investor Activity in 2026

The UK ophthalmology market continues to attract significant M&A and investment activity, although the focus of investors is gradually shifting.

Recent transactions suggest growing interest in platforms with a strong private pay proposition, particularly those able to combine surgical capacity with brand, patient experience and scalable operating models.

BGF’s investment into OCL Vision backs a premium private-pay platform to accelerate clinic rollout with brand-led marketing and a broader private-pay case mix. Cardinal’s €30m investment into Cathedral Eye Clinic is similar, funding expansion of a high-throughput surgical model across Ireland and the UK. Together they demonstrate clear appetite for scalable private-pay platforms.

EssilorLuxottica’s acquisition of Optegra represents a more strategic move. Rather than a conventional private equity platform investment, the transaction brings surgical ophthalmology into a broader vertically integrated eyecare ecosystem spanning diagnostics, lenses and retail.

The tilt towards private pay is likely being reinforced by a more challenging operating environment for NHS-focused providers. NHS England has proposed reductions in tariffs for core cataract procedures, with funding redirected towards increases in other ophthalmology services. At the same time, commissioning behaviour across ICBs has become more cautious around cataract volumes, with greater scrutiny of referral pathways and independent sector activity.

For providers heavily reliant on NHS cataract throughput, this creates a more complex environment in which pricing pressure and activity management both influence growth. Many operators are therefore likely to place greater emphasis on diversifying case mix, either through more complex procedures where tariffs are increasing or through the development of complementary private pay services.

Within the private pay segment, the market remains fragmented, with a large number of clinician-founded clinics operating on a relatively small scale. This fragmentation creates a natural consolidation opportunity for investors and larger platforms seeking to expand geographic coverage and surgical capacity.

The challenge, however, is often bridging the gap between perceived and transferable value. Many clinics are built around the reputation and referral base of a single clinician, which can make underwriting future earnings more difficult. Buyers therefore tend to focus less on individual reputation and more on the durability of demand, operational structure and the extent to which revenue can be sustained beyond the founding surgeon.

Overall, the ophthalmology market remains highly investable, but investor focus is becoming more selective. Capital is concentrating around platforms that combine operational scale with diversified payer exposure, while private pay capability is increasingly viewed as an important component of long-term growth.